Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04532411 · ClinicalTrials.gov registry record

COVID-19 Testing Sample Acquisition Throughput and Efficiency

A clinical trial, sponsored by Massachusetts General Hospital.

Completed
Registry status
28,948
Enrollment target

NCT04532411: Completed study, sponsored by Massachusetts General Hospital.

NCT04532411 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 28,948 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04532411 has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
28,948 participants
Enrollment target

Study Summary

This QI project seeks to evaluate the relative test sample acquisition throughput, personal protective equipment utilization, and relative operational costs of provider-administered COVID-19 (SARS-CoV-2) nasal samples with and with the use of HEPA-filtered, positive pressure isolation booths.

Primary Outcome

Samples acquired per hour using the Hexapod booth will be assessed as an average over a minimum of 12 weeks of testing compared to baseline throughput before April 16th.

Interventions

  • OTHER Personal Protective Testing Booth

Trial Details

FieldValue
Enrollment Target 28,948 participants
Start Date 2020-03-01
Est. Completion 2020-09-30
Massachusetts General Hospital

2,032 total trials

What the finished NCT04532411 record still lists

NCT04532411 is an observational study that tracks outcomes without assigning an intervention. Its 28,948 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 1 intervention - of which Personal Protective Testing Booth is the first listed.

NCT04532411 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04532411 about?

NCT04532411 is a clinical study titled "COVID-19 Testing Sample Acquisition Throughput and Efficiency". This QI project seeks to evaluate the relative test sample acquisition throughput, personal protective equipment utilization, and relative operational costs of provider-administered COVID-19 (SARS-CoV-2) nasal samples with and with the use of HEPA-filtered, positive pressure isolation booths.

What is the current status of trial NCT04532411?

This trial is currently completed. The enrollment target is 28,948 participants. The study started on 2020-03-01. Estimated completion is 2020-09-30.

What interventions are being tested in trial NCT04532411?

The interventions under investigation include: Personal Protective Testing Booth (OTHER).

Who is sponsoring clinical trial NCT04532411?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00684580 · 30,000 participants

    Protocol For Collecting Data On Patients With Childhood Cancer

  • NCT03053193 · 30,000 participants

    MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

  • NCT03689595 · 30,000 participants

    Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

  • NCT04834869 · 30,000 participants

    COVID-19 Vaccines Safety Tracking (CoVaST)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04532411, the US trial registry maintained by the National Library of Medicine. NCT04532411 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.